OTCMKTS:GNWSF - GeneNews Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0403 0.00 (0.00 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$0.0448
Today's Range$0.0403 - $0.0403
52-Week Range$0.0130 - $0.1134
Volume3,000 shs
Average Volume1,700 shs
Market Capitalization$6.38 million
P/E RatioN/A
Dividend YieldN/A
Beta4.2
GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is based in Richmond Hill, Canada.

Receive GNWSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNWSF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNWSF
CUSIPN/A
Phone905-209-2030

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$410,000.00
Book Value($0.03) per share

Profitability

Net Income$-2,940,000.00
Net Margins-2,524.26%

Miscellaneous

Employees16
Market Cap$6.38 million
OptionableNot Optionable

GeneNews (OTCMKTS:GNWSF) Frequently Asked Questions

What is GeneNews' stock symbol?

GeneNews trades on the OTCMKTS under the ticker symbol "GNWSF."

When is GeneNews' next earnings date?

GeneNews is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for GeneNews.

Has GeneNews been receiving favorable news coverage?

News headlines about GNWSF stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GeneNews earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term.

Who are some of GeneNews' key competitors?

Who are GeneNews' key executives?

GeneNews' management team includes the folowing people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D., Co-Founder
  • Mr. Warren Whitehead, Chief Accountant (Age 67)
  • Mr. David Suria, Sr. Scientist

How do I buy shares of GeneNews?

Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GeneNews' stock price today?

One share of GNWSF stock can currently be purchased for approximately $0.0403.

How big of a company is GeneNews?

GeneNews has a market capitalization of $6.38 million and generates $410,000.00 in revenue each year. GeneNews employs 16 workers across the globe.

What is GeneNews' official website?

The official website for GeneNews is http://www.genenews.com.

How can I contact GeneNews?

GeneNews' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected]


MarketBeat Community Rating for GeneNews (OTCMKTS GNWSF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote "Outperform" if you believe GNWSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNWSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel